Board of Directors
Dr. Zeldis, an experienced senior biopharmaceutical executive, is currently the CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation, based in Summit, New Jersey. He received his training in Internal Medicine at the UCLA Center for the Health Sciences and was a clinical and research fellow in gastroenterology at Massachusetts General Hospital and Harvard Medical School. Additionally, he was an Assistant Professor of Medicine at the Harvard Medical School, an Associate Professor of Medicine at the University of California, a Clinical Associate Professor of Medicine at Cornell Medical School and a Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswisk, New Jersey. Dr. Zeldis has published 112 peer reviewed articles and 24 reviews, book chapters, and editorials.
David Johnson was formerly president of the ConvaTec division of Bristol-Myers Squibb, Inc. until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.’s manufacturing and infrastructure into Europe. From 2008 through 2012, Mr. Johnson served as the chief executive officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.’s Board of Directors and the Board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an undergraduate business degree in marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of the University of Pennsylvania.
Joseph M. Leone is a nationally recognized expert in commercial lending to the small and midsize business (SMB) market. Mr. Leone spent more than 24 years with CIT Group, one of the nation’s largest SMB lenders, and held several senior-level positions at CIT, including Vice Chairman and Chief Financial Officer. Mr. Leone is a graduate of Baruch College (BBA in Accounting) and the Advanced Management Program at Harvard Business School.
Mr. Londoner, 42, is the founder, and currently serves as Chairman and CEO, of BioSig Technologies, Inc., a privately held medical technology company formed in 2009. BioSig Technologies is developing and commercializing a new system to more accurately treat patients suffering from Atrial Fibrillation, or irregular heartbeats. Mr. Londoner is also the Managing Partner of Endicott Management Partners, LLC., a private investment company focused on medical technology and consumer-related companies. From 1990-1997, Mr. Londoner was a Senior Vice President and Investment Officer at J. & W. Seligman & Co, Inc. and, at 24, was its youngest money manager. Mr. Londoner managed the Seligman Growth Fund and the Seligman Capital Fund. In addition, he co-managed over $2 billion of pension, corporate, endowment, and charitable trust assets.
Kenneth Pearsen, M.D. is currently the CEO of Western New York Radiology Associates. He is also the Chief of Radiology at Buffalo General Hospital, Chief of Service for Radiology Kaleida Health Care System and the CEO of Imaging Radiology Associates. Dr. Pearsen graduated summa cum laude from the University of Pennsylvania and received his M.D. from Columbia College of Physicians & Surgeons in New York.
Richard Rosenblum has been an active and productive force in the small and mid cap markets for over 16 years, advising, strategizing and raising over $500 million for both private and public companies during that time span. Among his other roles, Mr. Rosenblum has been a principal of Harborview Advisors since its inception. He previously was a Managing Director of Investment Banking for vFinance, Inc., a middle market investment banking and brokerage organization.
Jeffrey Sklar is the managing partner of Sklar, Heyman and Company LLP, a regional accounting firm, where he oversees the industry specialization team for non-bank financial institutions, as well as forensic and investigative auditing services. In addition to being a Certified Public Accountant (CPA), Mr. Sklar is a Certified Anti-Money Laundering Specialist (CAMS), a Certified Fraud Specialist (CFS) and Certified in Financial Forensics (CFF) by the American Institute of CPAs.
David Stefansky has been a principal of Harborview Advisors, LLC since 2004, the investment manager for Harborview Master Fund, L.P. and Harborview Value Master Fund, L.P. Harborview Master Fund, L.P. and Harborview Value Master Fund, L.P. are two investment funds focused primarily on investing in emerging growth public companies and private companies seeking to go public. Mr. Stefansky has taken an active role in structuring investments for each of Harborview Master Fund, L.P. and Harborview Value Master Fund, L.P. and regularly works with portfolio companies to help them grow and create shareholder value. Prior to forming Harborview Advisors, LLC, Mr. Stefansky held senior positions at several middle market investment banks in New York, where he raised and/or was responsible for direct investments of over $500 million in emerging growth companies.